The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Mitsubishi Tanabe Wins Arbitration Case over Gilenya Royalty
Mitsubishi Chemical Group said on February 14 that the International Chamber of Commerce (ICC) has delivered a decision in favor of its subsidiary, Mitsubishi Tanabe Pharma, in arbitration proceedings filed by Novartis over royalty payments tied to the multiple sclerosis…
To read the full story
Related Article
- Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
May 15, 2023
- Mitsubishi Chemical Ups Full-Year Outlook on Gilenya Royalty Win
February 20, 2023
- Mitsubishi Tanabe Incurs 6 Billion Yen Operating Loss as Flu Vaccine Project Dropped in US
May 14, 2020
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
- Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
February 21, 2019
BUSINESS
- Toa Out-Licenses Dry Eye Drug to South Korea’s JBK LAB
March 18, 2025
- Japan Approves Tablet Forms of Sleep Aid Melatobel: Nobelpharma
March 18, 2025
- Taiho Picks Up Araris, Bagging 3 Key Preclinical ADCs
March 18, 2025
- Novartis CEO Touts Plan to Amp Up Japan Investment, Add 50 Jobs for Early Trials
March 18, 2025
- Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
March 17, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…